Evidence map›Paper›PMID 38581388›Full record

ArticleACS applied bio materials2024

Intranasal Delivery of Carvedilol- and Quercetin-Encapsulated Cationic Nanoliposomes for Cardiovascular Targeting: Formulation and

Sweta Kar, Sabya Sachi Das, Sourav Kundu, Bidya Dhar Sahu, K Jayaram Kumar, Kavindra Kumar Kesari, Sandeep Kumar Singh

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS applied bio materials, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Sweta KarDepartment of Pharmaceutical Sciences and Technology, Birla Institute of Technology, Mesra, Ranchi 835215, Jharkhand, India.
Sabya Sachi DasSchool of Pharmaceutical and Population Health Informatics, DIT University, Dehradun 248009, Uttarakhand, India.ORCID 0000-0002-4042-8525
Sourav KunduDepartment of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Guwahati, Changsari 781101, Assam, India.
Bidya Dhar SahuDepartment of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Guwahati, Changsari 781101, Assam, India.
K Jayaram KumarDepartment of Pharmaceutical Sciences and Technology, Birla Institute of Technology, Mesra, Ranchi 835215, Jharkhand, India.
Kavindra Kumar KesariDepartment of Applied Physics, School of Science, Aalto University, 00076 Espoo, Finland.ORCID 0000-0003-3622-9555
Sandeep Kumar SinghDepartment of Pharmaceutical Sciences and Technology, Birla Institute of Technology, Mesra, Ranchi 835215, Jharkhand, India.ORCID 0000-0001-5702-4554
Birla Institute of Technology, Mesra · INNational Institute of Pharmaceutical Education and Research · INAalto University · FIDehradun Institute of Technology University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Carvedilol (CVD), an adrenoreceptor blocker, is a hydrophobic Biopharmaceutics Classification System class II drug with poor oral bioavailability due to which frequent dosing is essential to attain pharmacological effects. Quercetin (QC), a polyphenolic compound, is a potent natural antioxidant, but its oral dosing is restricted due to poor aqueous solubility and low oral bioavailability. To overcome the common limitations of both drugs and to attain synergistic cardioprotective effects, we formulated CVD- and QC-encapsulated cationic nanoliposomes (NLPs)

Indexed as

Administration, IntranasalCarvedilolLiposomesNanoparticlesParticle SizeQuercetinAnimalsAntioxidantsBiocompatible MaterialsCationsCell SurvivalMaterials TestingRatsAntioxidantsBiocompatible MaterialsCarvedilolCationsLiposomesQuercetinCardioprotectiveCarvedilolCationic nanoliposomesDrug release and permeationH9c2 cellsQuercetinROS

Identifiers

PMID38581388
PMCPMC11530090
OpenAlexW4394014136

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.